Epirubicin HCl

Catalog No.S1223 Batch:S122307

Print

Technical Data

Formula

C27H29NO11.HCl
Molecular Weight 579.98 CAS No. 56390-09-1
Solubility (25°C)* In vitro DMSO 100 mg/mL (172.41 mM)
Water 100 mg/mL (172.41 mM)
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Epirubicin HCl, a semisynthetic L-arabino derivative of doxorubicin, is an antineoplastic agent by inhibiting Topoisomerase. Epirubicin induces apoptosis.
Targets
Topoisomerase [1]
(Cell-free assay)
In vitro

Epirubicin, like doxorubicin, exerts its antitumor effects by complex with DNA, resulting in damage to DNA and interference with the synthesis of DNA, RNA, and proteins. Epirubicin may also affect the integrity and activity of cellular membranes. Maximal cell kill caused by Epirubicin occurs during the S phase of the cell cycle. With higher concentrations effects are also seen in early G2 as well as G1 and M phases. Epirubicin display antineoplastic activity against most cancer cells. Epirubicin is cytotoxic to Hepatoma G2 cells with IC50 of 1.6 μg/mL at 24hr. 1.6 μg/mL Epirubicin induces apoptosis of Hep G2 cells, and higher activity of catalase by 50%, Se-dependent glutathione peroxidase by 110%, Cu, Zn-superoxide dismutase by 172% and Mn-superoxide dismutase by 135%. Epirbicin increases the cellular expression of NADPH-CYP 450 reductase, and reduces GST-π expression.

In vivo

Epirubicin are clinically active against a broad range of tumor types, including breast cancer, malignant lymphomas, soft tissue sarcomas, lung cancer, pleural mesothelioma, gastrointestinal cancer, head and neck cancer, ovarian cancer, prostatic carcinoma, transitional bladder carcinoma and so on. Epirubicin at a dose of 3.5 mg/kg suppresses tumor mass of human breast tumor xenograft R-27 by 74.4 %.

Protocol (from reference)

Cell Assay:

[2]
  • Cell lines

    Human hepatocellular carcinoma cell Hep G2

  • Concentrations

    0.05-12 μg/mL

  • Incubation Time

    1 days

  • Method

    Hep G2 cells (500 cells/well, monolayer) are plated in a 96-well plate. The next day the cells are treated with Epirubicin in the medium. At the end of the incubation periods, 15% volume of MTT dye solution is added. After 1 hr of incubation at 37℃, an equal volume of solubilization/stop solution (dimethylsul-foxide) is added to each well for an additional 1 hr incubation. The absorbance of the reaction solution at 570 nm is recorded.
Animal Study:

[4]
  • Animal Models

    Human breast tumor xenograft R-27

  • Dosages

    3.5 mg/kg

  • Administration

    i.v. every 4 day for 3 times

References

  • https://pubmed.ncbi.nlm.nih.gov/3005521/
  • https://pubmed.ncbi.nlm.nih.gov/15520498/
  • https://pubmed.ncbi.nlm.nih.gov/8353070/
  • https://pubmed.ncbi.nlm.nih.gov/9821299/

Customer Product Validation

<p> </p><p>Growth inhibitory effects of Epirubicin human pancreatic cancer cells. MiaPaCa-2 cells were plated in triplicates into 48-well plates at a density of 10,000 cells/ml. After 24 hours, complete culture medium was changed into fresh low-serum-containing medium (0.5% FBS) containing DMSO (control) or indicated doses of Epirubicin (Selleckchem). Cell viability 48 hours after treatment was determined by AlamarBlue assay (Invitrogen) according to manufacturer's instructions. Results are expressed as percentages of control, which was arbitrarily assigned 100% viability, and represented as the mean ± standard deviation (SD) of the tripicate wells. </p>

, , Dr. Edita Aksamitiene from Thomas Jefferson University

Selleck's Epirubicin HCl Has Been Cited by 54 Publications

Combined Treatment of Tanshinone I and Epirubicin Revealed Enhanced Inhibition of Hepatocellular Carcinoma by Targeting PI3K/AKT/HIF-1α [ Drug Design, Development and Therapy, September 19, 2022, 3197-3213] PubMed: 36158238
Regularized Single-cell Imaging Enables Generalizable AI models for Stain-free Cell Viability Screening [ bioRxiv, September 11, 2025, 675708] PubMed: 41574984
A novel twelve-gene signature to predict neoadjuvant chemotherapy response and prognosis in breast cancer [ Frontiers in Immunology, October 19, 2022, 1035667] PubMed: 36341435
Anti-Tumor Effect of Apatinib and Relevant Mechanisms in Liposarcoma [ Frontiers in Oncology, November 17, 2021, 755553] PubMed: 34868934
CRISPRi/a Screens in Human iPSC-Derived Cardiomyocytes Identify Glycolytic Activation as a Druggable target for Doxorubicin-Induced Cardiotoxicity [ Cell Stem Cell, November 07, 2024, 1760-1776.e9]
Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer [ Oncotarget, December 21, 2018, 37439-37457] PubMed: 30647844
Heterogeneous therapy-resistant cancer cells have distinct and exploitable drug sensitivity profiles [ bioRxiv, April 25, 2025, 2025.04.25.650475] PubMed: 40654745
FGD3 mediates lytic cell death, enhancing efficacy and immunogenicity of chemotherapy agents in breast cancer [ J Exp Clin Cancer Res, 2025, 44(1):299] PubMed: 41225536
Multi-layer stratified oncology platform utilizing transcriptomics, prostate cancer organoids, and modeling of drug response [ J Exp Clin Cancer Res, 2025, 44(1):290] PubMed: 41094672
Platinum nanoparticles interact with epirubicin in size dependent manner and affect its biological activity [ Eur J Pharm Biopharm, 2025, 216:114866] PubMed: 40939769

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.